[
  {
    "ts": null,
    "headline": "Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density",
    "summary": "On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, “Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction i",
    "url": "https://finnhub.io/api/news?id=06d1e5d36a02fe7bfd46c7bdf0deb017bf9f954c6cd8097f928d51eacc5871fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731524360,
      "headline": "Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density",
      "id": 131338563,
      "image": "https://media.zenfs.com/en/Benzinga/080073f558eccf01c2a89d5cb120eb5e",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, “Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction i",
      "url": "https://finnhub.io/api/news?id=06d1e5d36a02fe7bfd46c7bdf0deb017bf9f954c6cd8097f928d51eacc5871fe"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?",
    "summary": "Amgen stock rebounded Wednesday, shaking off \"overdone\" fears that its monthly weight-loss shot causes excessive bone mineral density loss.",
    "url": "https://finnhub.io/api/news?id=d87b2705646608122bb5d3495676bd18c12ee054e10aed77026f78633c92a41f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731516902,
      "headline": "Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?",
      "id": 131327826,
      "image": "",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen stock rebounded Wednesday, shaking off \"overdone\" fears that its monthly weight-loss shot causes excessive bone mineral density loss.",
      "url": "https://finnhub.io/api/news?id=d87b2705646608122bb5d3495676bd18c12ee054e10aed77026f78633c92a41f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=65f6012c5ea0e44e60b33c92ec59a5c64e128ddf45c87ff22a35ae2e8aec756d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731515880,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 131415640,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=65f6012c5ea0e44e60b33c92ec59a5c64e128ddf45c87ff22a35ae2e8aec756d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) UBS Global Healthcare Conference November 13, 2024 1:15 PM ETCompany ParticipantsPeter Griffith - CFONarimon Honarpour - SVP,...",
    "url": "https://finnhub.io/api/news?id=620361f6d573df4644a0da490e5897b630f92adfbfaf1097dfbb07cb5bb55abd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731514749,
      "headline": "Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)",
      "id": 131333504,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. (NASDAQ:AMGN) UBS Global Healthcare Conference November 13, 2024 1:15 PM ETCompany ParticipantsPeter Griffith - CFONarimon Honarpour - SVP,...",
      "url": "https://finnhub.io/api/news?id=620361f6d573df4644a0da490e5897b630f92adfbfaf1097dfbb07cb5bb55abd"
    }
  },
  {
    "ts": null,
    "headline": "MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM",
    "summary": "NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Moore Law, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...",
    "url": "https://finnhub.io/api/news?id=f3e9182f59042221495f59f1445f9fddd800f8c993af16e67c91ea56cf35df84",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731511685,
      "headline": "MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM",
      "id": 131332364,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Moore Law, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...",
      "url": "https://finnhub.io/api/news?id=f3e9182f59042221495f59f1445f9fddd800f8c993af16e67c91ea56cf35df84"
    }
  },
  {
    "ts": null,
    "headline": "Understanding Cardiovascular Risk: The Role of LDL-C, Comorbidities and Early Intervention",
    "summary": "or bad cholesterol - is one of the most significant modifiable risk factors.1-5 For someone with established cardiovascular disease , the presence of an additional CV condition, or comorbidity, can...",
    "url": "https://finnhub.io/api/news?id=879771b4ab2f4f22003486e6199e5b81eb46fe16d237971ed0313327b541d6e8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731504544,
      "headline": "Understanding Cardiovascular Risk: The Role of LDL-C, Comorbidities and Early Intervention",
      "id": 131329565,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "or bad cholesterol - is one of the most significant modifiable risk factors.1-5 For someone with established cardiovascular disease , the presence of an additional CV condition, or comorbidity, can...",
      "url": "https://finnhub.io/api/news?id=879771b4ab2f4f22003486e6199e5b81eb46fe16d237971ed0313327b541d6e8"
    }
  },
  {
    "ts": null,
    "headline": "Dow up 186 points on gains for Home Depot, Goldman Sachs shares",
    "summary": "Dow up 186 points on gains for Home Depot, Goldman Sachs shares",
    "url": "https://finnhub.io/api/news?id=49df0e794ddc4c7911d2c7d1d683768ef5d05f9c9f51fb3533286208890b3659",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731497460,
      "headline": "Dow up 186 points on gains for Home Depot, Goldman Sachs shares",
      "id": 131413465,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow up 186 points on gains for Home Depot, Goldman Sachs shares",
      "url": "https://finnhub.io/api/news?id=49df0e794ddc4c7911d2c7d1d683768ef5d05f9c9f51fb3533286208890b3659"
    }
  },
  {
    "ts": null,
    "headline": "Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing",
    "summary": "An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.",
    "url": "https://finnhub.io/api/news?id=b0922ffea7b181e02dd8d21b1e81913e895f123fb61a58d18d7d4007fa9cae16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731496552,
      "headline": "Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing",
      "id": 131328460,
      "image": "https://imgproxy.divecdn.com/EN859DYilhxm347cu1Y-V6p2PlWosSDQz4Jti2zSt1U/g:nowe:0:0/c:1207:682/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODM5MjE3OTMuanBn.webp",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.",
      "url": "https://finnhub.io/api/news?id=b0922ffea7b181e02dd8d21b1e81913e895f123fb61a58d18d7d4007fa9cae16"
    }
  },
  {
    "ts": null,
    "headline": "Amgen dismisses bone density concerns related to its new weight-loss drug",
    "summary": "The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on Amgen's MariTide showed the drug had led to a drop in bone mineral density.  \"The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide,\" Amgen said, adding that it looks forward to data from its mid-stage study later this year.  Shares of Amgen rose 2% in premarket trade after the company's statement.",
    "url": "https://finnhub.io/api/news?id=9840a26fb16f6b326abb9d75b2850857ad84cd7c51191d4bfba00782188ba729",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731493479,
      "headline": "Amgen dismisses bone density concerns related to its new weight-loss drug",
      "id": 131327828,
      "image": "https://media.zenfs.com/en/reuters-finance.com/51e6e0bd8afa9d2931e8d0b817a5eff4",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on Amgen's MariTide showed the drug had led to a drop in bone mineral density.  \"The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide,\" Amgen said, adding that it looks forward to data from its mid-stage study later this year.  Shares of Amgen rose 2% in premarket trade after the company's statement.",
      "url": "https://finnhub.io/api/news?id=9840a26fb16f6b326abb9d75b2850857ad84cd7c51191d4bfba00782188ba729"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA",
    "summary": "Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.",
    "url": "https://finnhub.io/api/news?id=f8c35481a2d660f8cd69a63548109e2e2904a331ae88b38658fb4be7c48174cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731492000,
      "headline": "AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA",
      "id": 131327830,
      "image": "https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.",
      "url": "https://finnhub.io/api/news?id=f8c35481a2d660f8cd69a63548109e2e2904a331ae88b38658fb4be7c48174cd"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Tracking Well Above The Industry",
    "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
    "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731489024,
      "headline": "Johnson & Johnson: Tracking Well Above The Industry",
      "id": 131324406,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
      "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Says No Link Between MariTide, Bone Density Loss",
    "summary": "By Colin Kellaher Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more...",
    "url": "https://finnhub.io/api/news?id=61f47d66eddc59afbaf02a36bed9a8f7b0bf7ab84a6554f178af5c79d781aa54",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731479469,
      "headline": "Amgen Says No Link Between MariTide, Bone Density Loss",
      "id": 131321897,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more...",
      "url": "https://finnhub.io/api/news?id=61f47d66eddc59afbaf02a36bed9a8f7b0bf7ab84a6554f178af5c79d781aa54"
    }
  },
  {
    "ts": null,
    "headline": "Amgen sees no bone safety concerns around experimental obesity drug",
    "summary": "Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after data from an early-stage study dragged its stock 7% lower. ...",
    "url": "https://finnhub.io/api/news?id=e8acd37ae72a2eb9c3c1ebb7e3191ebb3776cea002ea06feca7c746056ff2347",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731475479,
      "headline": "Amgen sees no bone safety concerns around experimental obesity drug",
      "id": 131320653,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after data from an early-stage study dragged its stock 7% lower. ...",
      "url": "https://finnhub.io/api/news?id=e8acd37ae72a2eb9c3c1ebb7e3191ebb3776cea002ea06feca7c746056ff2347"
    }
  }
]